Skip to content

13F-HR filed by Elmind Capital, LP

Elmind Capital, LP filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 21:09:36 UTC, with 30 holding rows worth $403,836,290.

Accession
0001013594-26-001197
Filed
2026-11-16
Accepted by EDGAR
Ingested
Source
EDGAR daily index

Original filing

13F report for Q3 2026

A holdings report, 30 entries on the cover page, a total value of $403,836,290 stated on the cover page (in dollars after the unit check, H1), rows summing to $403,836,290 with VALUE read as dollars as filed, 13F file number 028-26468. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW1,110,000$35,975,100dollars as filed
LEGEND BIOTECH CORP52490G102SPONSORED ADS1,569,676$31,220,856dollars as filed
SYNDAX PHARMACEUTICALS INC87164F105COM1,605,000$30,174,000dollars as filed
COGENT BIOSCIENCES INC19240Q201COM866,742$27,753,079dollars as filed
RELAY THERAPEUTICS INC COM75943R102Stock1,465,279$26,448,286dollars as filed
AMYLYX PHARMACEUTICALS INC03237H101COM894,760$26,037,516dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM1,224,931$25,221,329dollars as filed
VAXCYTE INC COM92243G108Stock372,340$21,186,146dollars as filed
UROGEN PHARMA LTDM96088105COMMON STOCK491,100$19,953,393dollars as filed
TRAVERE THERAPEUTICS INC89422G107COM322,600$18,994,688dollars as filed
CULLINAN THERAPEUTICS INC230031106COM962,792$14,778,857dollars as filed
PHARVARIS NVN69605108COMMON STOCK455,750$14,456,390dollars as filed
VERA THERAPEUTICS INC92337R101COMMON STOCK436,518$14,095,166dollars as filed
CYTOMX THERAPEUTICS INC23284F105COMMON STOCK4,550,000$12,376,000dollars as filed
BEAM THERAPEUTICS INC07373V105COM476,338$11,646,464dollars as filed
NURIX THERAPEUTICS INC67080M103COMMON STOCK460,000$10,906,600dollars as filed
SUMMIT THERAPEUTICS INC86627T108COM493,820$8,350,496dollars as filed
UNITED THERAPEUTICS CORP DEL COM91307C102Stock15,000$8,128,350dollars as filed
IMMUNOCORE HLDGS PLC ADS45258D105ADR256,143$7,758,571dollars as filed
KRYSTAL BIOTECH INC COM501147102Stock22,000$7,316,320dollars as filed
ALUMIS INC022307102COM749,560$5,539,248dollars as filed
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock520,000$4,331,600dollars as filed
SUTRO BIOPHARMA INC869367201COMMON STOCK228,265$3,677,349dollars as filed
MBX BIOSCIENCES INC COM55287L101Stock61,000$3,575,820dollars as filed
DBV TECHNOLOGIES S A23306J309SPONSORED ADS265,000$3,116,400dollars as filed
SUPERNUS PHARMACEUTICALS868459108COM70,000$3,012,800dollars as filed
BIOMARIN PHARMACEUTICAL INC09061G101COM47,000$2,820,000dollars as filed
SEPTERNA INC COM81734D104Stock49,444$1,934,744dollars as filed
ALECTOR INC014442107COMMON STOCK915,902$1,694,419dollars as filed
DESIGN THERAPEUTICS INC25056L103COM107,900$1,356,303dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001013594-26-001197this filing2026-11-16